Subscribe to Newsletter

Fabian Gerlinghaus

The Power List 2021 – Advanced Medicine

Co-Founder and Chief Executive Officer at Cellares

“The biggest challenge commercial cell therapy developers are facing is their inability to scale manufacturing to meet patient demand. The one-dose-at-a-time approach is highly labor-intensive, failure prone, and extremely difficult to scale with manual methods. For example, to produce 10,000 patient doses, one needs to run 10,000 separate manufacturing processes – each of which takes weeks and includes around 50 manual processing steps and 80 hours of touch time. This is a logistical nightmare; even the most pioneering companies in the cell therapy field struggle to treat a few thousand patients per year because of the lack of scalable manufacturing technologies. But I’m most excited about the creation of true end-to-end automation of cell therapy manufacturing platforms as they’ll help accelerate access to life-saving cell therapies by resolving this manufacturing bottleneck. At Cellares, we believe the industry must move beyond ‘semi-automated’ processes, and toward the adoption of true automation. This is critical to de-risking the manufacturing process, reducing costs, and the risk of manufacturing failures, enabling cell therapy companies to treat significantly larger patient populations.”

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine